Integra LifeSciences (NASDAQ:IART) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Integra LifeSciences (NASDAQ:IART) from a hold rating to a buy rating in a research report released on Saturday,Wall Street Zen reports.

A number of other brokerages have also weighed in on IART. UBS Group set a $14.00 price objective on Integra LifeSciences and gave the company a “neutral” rating in a report on Tuesday, October 27th. Wells Fargo & Company set a $13.00 target price on Integra LifeSciences and gave the stock an “equal weight” rating in a report on Thursday, October 22nd. Citizens Jmp dropped their target price on Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Thursday, October 22nd. Truist Financial set a $13.00 target price on Integra LifeSciences and gave the company a “hold” rating in a research report on Friday, October 23rd. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a report on Monday, October 26th. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $16.12.

Integra LifeSciences Trading Up 6.7%

Shares of NASDAQ IART opened at $13.61 on Friday. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.11. The stock has a market capitalization of $1.06 billion, a P/E ratio of 80.06, a price-to-earnings-growth ratio of 0.48 and a beta of 1.21. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The business has a fifty day moving average price of $14.77 and a 200 day moving average price of $14.09.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.03. The firm had revenue of $411.18 million for the quarter, compared to the consensus estimate of $413.16 million. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. During the same period in the previous year, the business earned ($0.07) EPS. Equities research analysts expect that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Paradigm Capital Management Inc. NY acquired a new stake in Integra LifeSciences during the second quarter valued at $61,766,000. Bank of America Corp DE increased its holdings in Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after buying an additional 589,408 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Integra LifeSciences in the second quarter worth about $8,723,000. Access Investment Management LLC raised its position in shares of Integra LifeSciences by 72.0% in the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after acquiring an additional 268,085 shares during the period. Finally, Glenmede Trust Co. NA boosted its stake in shares of Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.